Matches in Wikidata for { <http://www.wikidata.org/entity/Q37743160> ?p ?o ?g. }
- Q37743160 description "article científic" @default.
- Q37743160 description "article scientifique" @default.
- Q37743160 description "articolo scientifico" @default.
- Q37743160 description "artigo científico" @default.
- Q37743160 description "artículu científicu espublizáu en 2017" @default.
- Q37743160 description "bilimsel makale" @default.
- Q37743160 description "scientific article published on 22 March 2017" @default.
- Q37743160 description "vedecký článok" @default.
- Q37743160 description "vetenskaplig artikel" @default.
- Q37743160 description "videnskabelig artikel" @default.
- Q37743160 description "vědecký článek" @default.
- Q37743160 description "wetenschappelijk artikel" @default.
- Q37743160 description "wissenschaftlicher Artikel" @default.
- Q37743160 description "наукова стаття, опублікована в березні 2017" @default.
- Q37743160 description "научни чланак" @default.
- Q37743160 description "գիտական հոդված հրատարակված 2017 թվականի մարտի 22-ին" @default.
- Q37743160 description "مقالة علمية نشرت في 22 مارس 2017" @default.
- Q37743160 name "Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial" @default.
- Q37743160 name "Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial" @default.
- Q37743160 name "Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial" @default.
- Q37743160 type Item @default.
- Q37743160 label "Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial" @default.
- Q37743160 label "Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial" @default.
- Q37743160 label "Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial" @default.
- Q37743160 prefLabel "Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial" @default.
- Q37743160 prefLabel "Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial" @default.
- Q37743160 prefLabel "Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial" @default.
- Q37743160 P1433 Q37743160-CCECC155-EE64-4081-A87C-12C92CC1E154 @default.
- Q37743160 P1476 Q37743160-20BD2D3F-440E-40E2-B310-CC0E792AFE6D @default.
- Q37743160 P2093 Q37743160-1CDE3246-A842-4871-A5E3-9F37E68E5D61 @default.
- Q37743160 P2093 Q37743160-242DB49D-DDF4-4538-AC44-7ADD0AEB562C @default.
- Q37743160 P2093 Q37743160-5D081969-A551-42DA-BF7D-962FF8A205C5 @default.
- Q37743160 P2093 Q37743160-8930E3ED-2DF4-41EA-BC00-CC3549172DA3 @default.
- Q37743160 P2093 Q37743160-A9D1847B-D840-46C8-B21E-0F53258C7328 @default.
- Q37743160 P2860 Q37743160-0012B68C-38C2-4838-81A6-823E10E1DD6F @default.
- Q37743160 P2860 Q37743160-06757B14-AC02-4B70-9C6E-C64D5BA466B3 @default.
- Q37743160 P2860 Q37743160-0F86AF18-FCA7-49C6-901C-3C470B16DED6 @default.
- Q37743160 P2860 Q37743160-13576559-6F74-48D6-9E81-76DEE96486AE @default.
- Q37743160 P2860 Q37743160-3E2F143C-AE4C-4FB3-8E51-8FC41BA968AD @default.
- Q37743160 P2860 Q37743160-3FBD3E0C-FB95-4EDD-AA42-6918378DC6AA @default.
- Q37743160 P2860 Q37743160-4693B18F-E6D6-4BF2-BB4E-061047FE4245 @default.
- Q37743160 P2860 Q37743160-58BF657B-F57B-4FCC-9543-67C305DCAB52 @default.
- Q37743160 P2860 Q37743160-63C176B6-FA15-4F4C-B469-FC794FCFB1E5 @default.
- Q37743160 P2860 Q37743160-726FDC6A-0743-4211-83C1-0F6F3A35B71E @default.
- Q37743160 P2860 Q37743160-7E34623F-DDC7-4A06-81AB-36AF511DB0D2 @default.
- Q37743160 P2860 Q37743160-88DCC416-703A-4496-83C6-8AA7B85AF6C2 @default.
- Q37743160 P2860 Q37743160-9CD7D7A1-A0E9-44E8-A5D5-1DBEC5793DB6 @default.
- Q37743160 P2860 Q37743160-A0782F83-85F3-4CEB-BDE2-12C409CA044F @default.
- Q37743160 P2860 Q37743160-B6D6602B-0B95-497E-9790-058CE1A0BB3E @default.
- Q37743160 P2860 Q37743160-B92CD273-79AD-4C18-8EFE-880B220F1BAD @default.
- Q37743160 P2860 Q37743160-BF69DD53-7435-4286-8E7F-E2FD0BA5D470 @default.
- Q37743160 P2860 Q37743160-C3031C25-82EB-4126-A24F-416708848717 @default.
- Q37743160 P2860 Q37743160-CAAB556F-AD43-40DA-965A-4CB084376722 @default.
- Q37743160 P2860 Q37743160-CCF1403F-9061-49AD-A489-52E0C3994C3C @default.
- Q37743160 P2860 Q37743160-CD66B9A5-7D1A-4012-8E02-34D631170002 @default.
- Q37743160 P2860 Q37743160-CD81863A-7174-4C8D-BCFC-D395B8082C27 @default.
- Q37743160 P2860 Q37743160-CE92DE10-0E02-4D3A-89F8-FA595A6EF5B1 @default.
- Q37743160 P2860 Q37743160-D0C110C9-3365-4973-926E-EE546DB21C3E @default.
- Q37743160 P2860 Q37743160-D391B829-4C0A-490C-9B46-386C80906071 @default.
- Q37743160 P2860 Q37743160-D4814282-0CE7-4E7E-9A89-5DB8A98E9E4A @default.
- Q37743160 P2860 Q37743160-D6914B26-65CC-413C-BB75-A0AD7ACE991A @default.
- Q37743160 P2860 Q37743160-D73B58FC-1AE1-4E6E-9B3F-D7512E82F8EB @default.
- Q37743160 P2860 Q37743160-DB14E3BC-FAC6-4903-8DF8-F1D51A4449A7 @default.
- Q37743160 P2860 Q37743160-DCF8C85C-735C-4B5A-97A8-A68DEF9003F1 @default.
- Q37743160 P2860 Q37743160-DD1B8276-ECE7-4492-9ED2-7716EC342198 @default.
- Q37743160 P2860 Q37743160-E051B973-12A7-4ABF-9583-35836CA3CE46 @default.
- Q37743160 P2860 Q37743160-EBED54A0-B640-4E0D-89A5-6AB8F33E1116 @default.
- Q37743160 P304 Q37743160-56994930-D29A-4E63-9332-8E007CC50280 @default.
- Q37743160 P31 Q37743160-C19A6EEF-E4E8-4E9B-AC91-57D25C36CF67 @default.
- Q37743160 P356 Q37743160-9CC712D4-F13B-43D2-9C08-080C2B5E3192 @default.
- Q37743160 P433 Q37743160-C5C5F540-5E66-4FA3-B387-204381BCB36F @default.
- Q37743160 P478 Q37743160-EE9F7F38-046A-4FBE-AE64-BD2E60D27707 @default.
- Q37743160 P50 Q37743160-25CBDCF3-093C-415F-A26E-94B5D70881B3 @default.
- Q37743160 P577 Q37743160-CD2ABDCE-0FA6-497E-877B-B3C198983622 @default.
- Q37743160 P698 Q37743160-7135EA44-EE7E-41DF-B711-4A5723D0391D @default.
- Q37743160 P921 Q37743160-23B3C984-ADF9-41C4-92BC-1C57AC886B9A @default.
- Q37743160 P921 Q37743160-7CA41D98-366E-4712-8357-C540B61D78FA @default.
- Q37743160 P921 Q37743160-C5B1ECE8-9C94-4870-90FA-EC527E4DD32B @default.
- Q37743160 P921 Q37743160-FCBD3A9E-7F0E-410F-BBAE-A7456ECBF513 @default.
- Q37743160 P932 Q37743160-095AB756-7364-4185-9A08-39820D824CEE @default.
- Q37743160 P356 WO.2017.66661 @default.
- Q37743160 P698 28435404 @default.
- Q37743160 P1433 Q26841968 @default.
- Q37743160 P1476 "Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial" @default.
- Q37743160 P2093 "Fateme Shojaiyan" @default.
- Q37743160 P2093 "Fereshte Abbasvandi" @default.
- Q37743160 P2093 "Mehrdad Payandeh" @default.
- Q37743160 P2093 "Safa Najafi" @default.
- Q37743160 P2093 "Vahideh Shafaei" @default.
- Q37743160 P2860 Q26801549 @default.
- Q37743160 P2860 Q28328220 @default.
- Q37743160 P2860 Q28339648 @default.
- Q37743160 P2860 Q29547513 @default.
- Q37743160 P2860 Q33619867 @default.
- Q37743160 P2860 Q33764004 @default.
- Q37743160 P2860 Q33903066 @default.
- Q37743160 P2860 Q34207498 @default.
- Q37743160 P2860 Q34658655 @default.
- Q37743160 P2860 Q35619636 @default.
- Q37743160 P2860 Q35740423 @default.